The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy

Nephrology Dialysis Transplantation

Volumn 14, Issue 10, 1999, Pages 2379-2386

  Yokoyama, Hitoshi ^a,b   Goshima, Satoshi ^a   Wada, Takashi ^a   Takaeda, Masayoshi ^a   Furuichi, Kengo ^a   Kobayashi, Ken Ichi ^a,b   Kida, Hiroshi ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Complement; Electron dense deposits; Immune globulin therapy; Membranous nephropathy

Indexed keywords

IMMUNOGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FEMALE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CHILD; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032827023     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.10.2379     Document Type: Article

References (24)

1. Noel LH, Zanetti M, Droz D, Barbanel C. Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med 1979; 66: 82-90
2. Cameron JS. Membranous nephropathy - Still a treatment dilemma. N Engl J Med 1992; 327: 638-639
3. Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 85-89
4. Kida H, Asamoto T, Yokoyama H, Tomosugi N, Hattori N. Long-term prognosis of membranous nephropathy. Clin Nephrol 1986; 25: 64-69
5. Ogi M, Yokoyama H, Tomosugi N et al. Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis 1994; 24: 427-436
6. Marx BE, Marx M. Prognosis of idiopathic membranous nephropathy: A methodologic meta-analysis. Kidney Int 1997; 51: 873-879
7. Imbach P, Barandum S, D'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-1231
8. Law C, Marcaccio M, Tam P, Heddle N, Kelton JG. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 1997; 336: 1494-1498
9. Furusho K, Kamiya T, Nakano H et al. High-dose intravenous gammaglobulin for Kawasaki syndrome. Lancet 1984; 2: 1055-1057
10. Lin CY, Hsu HC, Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 1989; 53: 303-310
11. Becker BN, Fuchs H, Hakim R. Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. J Am Soc Nephrol 1995; 5: 1745-1750
12. Rostoker G, Deavaux-Belghiti D, Pilatte Y et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schoenlein purpura. Ann Intern Med 1994; 120: 476-484
13. Jayne DRW, Davies MJ, Fox CJV, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337: 1137-1139
14. Palla R, Cirami C, Panichi V, Bianchi AM, Parrini M, Grazi G. Intravenous immunoglobulin therapy of membranous nephropathy: Efficacy and safety. Clin Nephrol 1991; 35: 98-104
15. Nangaku M, Pippin J, Richardson CA et al. Beneficial effects of systemic immunoglobulins in experimental membranous nephropathy. Kidney Int 1996; 50: 2054-2062
16. Rosen S, Tornroth T, Bernard DB. Membranous glomerulonephritis. In: Tisher CC, Brenner BM, eds. Renal Pathology with Clinical and Functional Correlations. Lippincott, Philadelphia, 1989; 196-227
17. SAS Technical Report: P-179 Additional SAS/STAT Procedures, Release 6 03 Edition. Cary, NC, SAS Institute, 1988
18. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107-116
19. Smiley JD, Talbert MG. High-dose intravenous gamma globulin therapy: How does it work? Am J Med Sci 1995; 309: 295-303
20. Tsubakio T, Kurata Y, Katagiri S et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose y-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immuno. 1983; 53: 679-702
21. Bussel J, Lalezari P, Hilgartner M et al. Reversal of neutropenia with intravenous gammaglobulin in autoimmune neutropenia of infancy. Blood 1983; 62: 398-400
22. Durandy A, Fisher A, Griscelli C. Dysfunctions of pokeweed mitogen-stimulated T and B lymphocyte responses induced by gammaglobulin therapy. J Clin Invest 1981; 67: 867-877
23. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991; 325: 110-117
24. Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis 1996; 451-453